Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Hussein A TawbiPeter A ForsythF Stephen HodiChristopher D LaoStergios J MoschosOmid HamidMichael B AtkinsKarl LewisReena P ThomasJohn A GlaspySekwon JangAlain P AlgaziNikhil I KhushalaniMichael A PostowAnna C PavlickMarc S ErnstoffDavid A ReardonIgor PuzanovRagini R KudchadkarAhmad A TarhiniAnne SumbulJasmine I RizzoKim A MargolinPublished in: Neuro-oncology (2021)
Nivolumab plus ipilimumab provides durable clinical benefit for asymptomatic patients with MBM and should be considered for first-line therapy. This regimen has limited activity in MBM patients with neurologic symptoms and/or requiring corticosteroids, supporting the need for alternative approaches and methods to reduce the dependency on corticosteroids. Clinical trial registration. ClinicalTrials.gov, NCT02320058.